LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Pharmacological mTOR-inhibition facilitates clearance of AD-related tau aggregates in the mouse brain.

    Morawe, Martina P / Liao, Fan / Amberg, Willi / van Bergeijk, Jeroen / Chang, Rui / Gulino, Mary / Hamilton, Caitlin / Hoft, Carolin / Lumpkin, Casey / Mastis, Bryan / McGlame, Emily / Nuber, Judith / Plaas, Christian / Ravikumar, Brinda / Roy, Kaushambi / Schanzenbächer, Marion / Tierno, Joseph / Lakics, Viktor / Dellovade, Tammy /
    Townsend, Matthew

    European journal of pharmacology

    2022  Volume 934, Page(s) 175301

    Abstract: In this study we aimed to reduce tau pathology, a hallmark of Alzheimer's Disease (AD), by activating mTOR-dependent autophagy in a transgenic mouse model of tauopathy by long-term dosing of animals with mTOR-inhibitors. Rapamycin treatment reduced the ... ...

    Abstract In this study we aimed to reduce tau pathology, a hallmark of Alzheimer's Disease (AD), by activating mTOR-dependent autophagy in a transgenic mouse model of tauopathy by long-term dosing of animals with mTOR-inhibitors. Rapamycin treatment reduced the burden of hyperphosphorylated and aggregated pathological tau in the cerebral cortex only when applied to young mice, prior to the emergence of pathology. Conversely, PQR530 which exhibits better brain exposure and superior pharmacokinetic properties, reduced tau pathology even when the treatment started after the onset of pathology. Our results show that dosing animals twice per week with PQR530 resulted in intermittent, rather than sustained target engagement. Nevertheless, this pulse-like mTOR inhibition followed by longer intervals of re-activation was sufficient to reduce tau pathology in the cerebral cortex in P301S tau transgenic mice. This suggests that balanced therapeutic dosing of blood-brain-barrier permeable mTOR-inhibitors can result in a disease-modifying effect in AD and at the same time prevents toxic side effects due to prolonged over activation of autophagy.
    MeSH term(s) Animals ; Mice ; Alzheimer Disease/drug therapy ; Alzheimer Disease/pathology ; tau Proteins/metabolism ; TOR Serine-Threonine Kinases/metabolism ; Mice, Transgenic ; Brain ; Sirolimus/pharmacology ; Disease Models, Animal
    Chemical Substances tau Proteins ; TOR Serine-Threonine Kinases (EC 2.7.11.1) ; Sirolimus (W36ZG6FT64)
    Language English
    Publishing date 2022-09-30
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 80121-5
    ISSN 1879-0712 ; 0014-2999
    ISSN (online) 1879-0712
    ISSN 0014-2999
    DOI 10.1016/j.ejphar.2022.175301
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: De Novo Design, Synthesis, and Biological Evaluation of 3,4-Disubstituted Pyrrolidine Sulfonamides as Potent and Selective Glycine Transporter 1 Competitive Inhibitors.

    Wang, Ying / Zhao, Hongyu / Brewer, Jason T / Li, Huanqiu / Lao, Yanbin / Amberg, Willi / Behl, Berthold / Akritopoulou-Zanze, Irini / Dietrich, Justin / Lange, Udo E W / Pohlki, Frauke / Hoft, Carolin / Hornberger, Wilfried / Djuric, Stevan W / Sydor, Jens / Mezler, Mario / Relo, Ana Lucia / Vasudevan, Anil

    Journal of medicinal chemistry

    2018  Volume 61, Issue 17, Page(s) 7486–7502

    Abstract: The development of glycine transporter 1 (GlyT1) inhibitors may offer putative treatments for schizophrenia and other disorders associated with hypofunction of the glutaminergic N-methyl-d-aspartate (NMDA) receptor. Herein, we describe the synthesis and ... ...

    Abstract The development of glycine transporter 1 (GlyT1) inhibitors may offer putative treatments for schizophrenia and other disorders associated with hypofunction of the glutaminergic N-methyl-d-aspartate (NMDA) receptor. Herein, we describe the synthesis and biological evaluation of a series of 3,4-disubstituted pyrrolidine sulfonamides as competitive GlyT1 inhibitors that arose from de novo scaffold design. Relationship of chemical structure to drug-drug interaction (DDI) and bioactivation was mechanistically investigated. Murine studies were strategically incorporated into the screening funnel to provide early assessments of in vivo target occupancy (TO) by ex vivo binding studies. Advanced compounds derived from iterative structure-activity relationship (SAR) studies possessed high potency in ex vivo binding studies and good brain penetration, promising preliminary in vivo efficacy, acceptable preclinical pharmacokinetics, and manageable DDI and bioactivation liabilities.
    MeSH term(s) Animals ; Brain/drug effects ; Brain/metabolism ; Chemistry Techniques, Synthetic ; Dogs ; Dose-Response Relationship, Drug ; Drug Design ; Glycine Plasma Membrane Transport Proteins/antagonists & inhibitors ; Glycine Plasma Membrane Transport Proteins/metabolism ; Humans ; Madin Darby Canine Kidney Cells ; Male ; Mice, Inbred Strains ; Microsomes, Liver/drug effects ; Motor Activity/drug effects ; Oocytes/drug effects ; Oocytes/metabolism ; Pyrrolidines/chemistry ; Pyrrolidinones/adverse effects ; Rats, Sprague-Dawley ; Structure-Activity Relationship ; Sulfonamides/chemistry ; Xenopus
    Chemical Substances Glycine Plasma Membrane Transport Proteins ; Pyrrolidines ; Pyrrolidinones ; SLC6A9 protein, human ; Slc6a9 protein, mouse ; Sulfonamides ; L 687414 (132695-96-6)
    Language English
    Publishing date 2018-07-17
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 218133-2
    ISSN 1520-4804 ; 0022-2623
    ISSN (online) 1520-4804
    ISSN 0022-2623
    DOI 10.1021/acs.jmedchem.8b00295
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Discovery of Novel Aminotetralines and Aminochromanes as Selective and Competitive Glycine Transporter 1 (GlyT1) Inhibitors.

    Amberg, Willi / Lange, Udo E W / Ochse, Michael / Pohlki, Frauke / Behl, Berthold / Relo, Ana Lucia / Hornberger, Wilfried / Hoft, Carolin / Mezler, Mario / Sydor, Jens / Wang, Ying / Zhao, Hongyu / Brewer, Jason T / Dietrich, Justin / Li, Huanqiu / Akritopoulou-Zanze, Irini / Lao, Yanbin / Hannick, Steven M / Ku, Yi-Yin /
    Vasudevan, Anil

    Journal of medicinal chemistry

    2018  Volume 61, Issue 17, Page(s) 7503–7524

    Abstract: The glycine transporter 1 (GlyT1) has emerged as a key novel target for the treatment of schizophrenia. Herein, we report the synthesis and biological evaluation of aminotetralines and aminochromanes as novel classes of competitive GlyT1 inhibitors. ... ...

    Abstract The glycine transporter 1 (GlyT1) has emerged as a key novel target for the treatment of schizophrenia. Herein, we report the synthesis and biological evaluation of aminotetralines and aminochromanes as novel classes of competitive GlyT1 inhibitors. Starting from a high-throughput screening hit, structure-activity relationship studies led first to the discovery of aminotetralines displaying high GlyT1 potency and selectivity, with favorable pharmacokinetic properties. Systematic investigations of various parameters (e.g., topological polar surface area, number of hydrogen bond donors) guided by ex vivo target occupancy evaluation resulted in lead compounds possessing favorable brain penetration properties as for (7 S,8 R)-27a. Further optimization revealed compounds with reduced efflux liabilities as for aminochromane 51b. In an in vivo efficacy model (7 S,8 R)-27a, dose-dependently reversed L-687,414 induced hyperlocomotion in mice with an ED
    MeSH term(s) ATP Binding Cassette Transporter, Subfamily B/genetics ; ATP Binding Cassette Transporter, Subfamily B/metabolism ; Animals ; Binding, Competitive ; Brain/drug effects ; Brain/metabolism ; Chromans/chemistry ; Dose-Response Relationship, Drug ; Female ; Glycine Plasma Membrane Transport Proteins/antagonists & inhibitors ; Glycine Plasma Membrane Transport Proteins/metabolism ; High-Throughput Screening Assays/methods ; Humans ; Male ; Mice, Inbred C57BL ; Motor Activity/drug effects ; Oocytes/drug effects ; Oocytes/metabolism ; Pyrrolidinones/adverse effects ; Rats, Sprague-Dawley ; Structure-Activity Relationship ; Tetrahydronaphthalenes/chemistry ; Xenopus
    Chemical Substances ATP Binding Cassette Transporter, Subfamily B ; Chromans ; Glycine Plasma Membrane Transport Proteins ; Pyrrolidinones ; SLC6A9 protein, human ; Slc6a9 protein, mouse ; Tetrahydronaphthalenes ; L 687414 (132695-96-6) ; multidrug resistance protein 3 (9EI49ZU76O)
    Language English
    Publishing date 2018-08-27
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 218133-2
    ISSN 1520-4804 ; 0022-2623
    ISSN (online) 1520-4804
    ISSN 0022-2623
    DOI 10.1021/acs.jmedchem.8b00300
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model.

    Dallas, Shannon / Salphati, Laurent / Gomez-Zepeda, David / Wanek, Thomas / Chen, Liangfu / Chu, Xiaoyan / Kunta, Jeevan / Mezler, Mario / Menet, Marie-Claude / Chasseigneaux, Stephanie / Declèves, Xavier / Langer, Oliver / Pierre, Esaie / DiLoreto, Karen / Hoft, Carolin / Laplanche, Loic / Pang, Jodie / Pereira, Tony / Andonian, Clara /
    Simic, Damir / Rode, Anja / Yabut, Jocelyn / Zhang, Xiaolin / Scheer, Nico

    Molecular pharmacology

    2016  Volume 89, Issue 5, Page(s) 492–504

    Abstract: Breast cancer resistance protein (BCRP) is expressed in various tissues, such as the gut, liver, kidney and blood brain barrier (BBB), where it mediates the unidirectional transport of substrates to the apical/luminal side of polarized cells. Thereby ... ...

    Abstract Breast cancer resistance protein (BCRP) is expressed in various tissues, such as the gut, liver, kidney and blood brain barrier (BBB), where it mediates the unidirectional transport of substrates to the apical/luminal side of polarized cells. Thereby BCRP acts as an efflux pump, mediating the elimination or restricting the entry of endogenous compounds or xenobiotics into tissues and it plays important roles in drug disposition, efficacy and safety. Bcrp knockout mice (Bcrp(-/-)) have been used widely to study the role of this transporter in limiting intestinal absorption and brain penetration of substrate compounds. Here we describe the first generation and characterization of a mouse line humanized for BCRP (hBCRP), in which the mouse coding sequence from the start to stop codon was replaced with the corresponding human genomic region, such that the human transporter is expressed under control of the murineBcrppromoter. We demonstrate robust human and loss of mouse BCRP/Bcrp mRNA and protein expression in the hBCRP mice and the absence of major compensatory changes in the expression of other genes involved in drug metabolism and disposition. Pharmacokinetic and brain distribution studies with several BCRP probe substrates confirmed the functional activity of the human transporter in these mice. Furthermore, we provide practical examples for the use of hBCRP mice to study drug-drug interactions (DDIs). The hBCRP mouse is a promising model to study the in vivo role of human BCRP in limiting absorption and BBB penetration of substrate compounds and to investigate clinically relevant DDIs involving BCRP.
    MeSH term(s) ATP Binding Cassette Transporter, Subfamily G, Member 2 ; ATP-Binding Cassette Transporters/antagonists & inhibitors ; ATP-Binding Cassette Transporters/chemistry ; ATP-Binding Cassette Transporters/genetics ; ATP-Binding Cassette Transporters/metabolism ; Animals ; Biological Availability ; Biotransformation/drug effects ; Blood-Brain Barrier/drug effects ; Blood-Brain Barrier/metabolism ; Drug Interactions ; Female ; Gene Expression Regulation/drug effects ; Gene Knock-In Techniques ; Humans ; Intestinal Absorption/drug effects ; Male ; Membrane Transport Modulators/blood ; Membrane Transport Modulators/metabolism ; Membrane Transport Modulators/pharmacokinetics ; Membrane Transport Modulators/pharmacology ; Mice, Inbred C57BL ; Mice, Knockout ; Mice, Transgenic ; Neoplasm Proteins/antagonists & inhibitors ; Neoplasm Proteins/chemistry ; Neoplasm Proteins/genetics ; Neoplasm Proteins/metabolism ; Promoter Regions, Genetic/drug effects ; RNA, Messenger/metabolism ; Recombinant Proteins/chemistry ; Recombinant Proteins/metabolism ; Tissue Distribution/drug effects ; Xenobiotics/blood ; Xenobiotics/metabolism ; Xenobiotics/pharmacokinetics ; Xenobiotics/pharmacology
    Chemical Substances ABCG2 protein, human ; ATP Binding Cassette Transporter, Subfamily G, Member 2 ; ATP-Binding Cassette Transporters ; Abcg2 protein, mouse ; Membrane Transport Modulators ; Neoplasm Proteins ; RNA, Messenger ; Recombinant Proteins ; Xenobiotics
    Language English
    Publishing date 2016-02-18
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 124034-1
    ISSN 1521-0111 ; 0026-895X
    ISSN (online) 1521-0111
    ISSN 0026-895X
    DOI 10.1124/mol.115.102079
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes.

    Darwich, Adam S / Margolskee, Alison / Pepin, Xavier / Aarons, Leon / Galetin, Aleksandra / Rostami-Hodjegan, Amin / Carlert, Sara / Hammarberg, Maria / Hilgendorf, Constanze / Johansson, Pernilla / Karlsson, Eva / Murphy, Dónal / Tannergren, Christer / Thörn, Helena / Yasin, Mohammed / Mazuir, Florent / Nicolas, Olivier / Ramusovic, Sergej / Xu, Christine /
    Pathak, Shriram M / Korjamo, Timo / Laru, Johanna / Malkki, Jussi / Pappinen, Sari / Tuunainen, Johanna / Dressman, Jennifer / Hansmann, Simone / Kostewicz, Edmund / He, Handan / Heimbach, Tycho / Wu, Fan / Hoft, Carolin / Pang, Yan / Bolger, Michael B / Huehn, Eva / Lukacova, Viera / Mullin, James M / Szeto, Ke X / Costales, Chester / Lin, Jian / McAllister, Mark / Modi, Sweta / Rotter, Charles / Varma, Manthena / Wong, Mei / Mitra, Amitava / Bevernage, Jan / Biewenga, Jeike / Van Peer, Achiel / Lloyd, Richard / Shardlow, Carole / Langguth, Peter / Mishenzon, Irina / Nguyen, Mai Anh / Brown, Jonathan / Lennernäs, Hans / Abrahamsson, Bertil

    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

    2016  Volume 96, Page(s) 626–642

    Abstract: Three Physiologically Based Pharmacokinetic software packages (GI-Sim, Simcyp® Simulator, and GastroPlus™) were evaluated as part of the Innovative Medicine Initiative Oral Biopharmaceutics Tools project (OrBiTo) during a blinded "bottom-up" anticipation ...

    Abstract Three Physiologically Based Pharmacokinetic software packages (GI-Sim, Simcyp® Simulator, and GastroPlus™) were evaluated as part of the Innovative Medicine Initiative Oral Biopharmaceutics Tools project (OrBiTo) during a blinded "bottom-up" anticipation of human pharmacokinetics. After data analysis of the predicted vs. measured pharmacokinetics parameters, it was found that oral bioavailability (F
    MeSH term(s) Administration, Oral ; Biopharmaceutics/methods ; Computer Simulation ; Drug Evaluation, Preclinical/methods ; Forecasting ; Humans ; Intestinal Absorption/drug effects ; Intestinal Absorption/physiology ; Models, Biological ; Pharmaceutical Preparations/administration & dosage ; Pharmaceutical Preparations/classification ; Pharmaceutical Preparations/metabolism
    Chemical Substances Pharmaceutical Preparations
    Language English
    Publishing date 2016-09-28
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1154366-8
    ISSN 1879-0720 ; 0928-0987
    ISSN (online) 1879-0720
    ISSN 0928-0987
    DOI 10.1016/j.ejps.2016.09.037
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results.

    Margolskee, Alison / Darwich, Adam S / Pepin, Xavier / Aarons, Leon / Galetin, Aleksandra / Rostami-Hodjegan, Amin / Carlert, Sara / Hammarberg, Maria / Hilgendorf, Constanze / Johansson, Pernilla / Karlsson, Eva / Murphy, Dónal / Tannergren, Christer / Thörn, Helena / Yasin, Mohammed / Mazuir, Florent / Nicolas, Olivier / Ramusovic, Sergej / Xu, Christine /
    Pathak, Shriram M / Korjamo, Timo / Laru, Johanna / Malkki, Jussi / Pappinen, Sari / Tuunainen, Johanna / Dressman, Jennifer / Hansmann, Simone / Kostewicz, Edmund / He, Handan / Heimbach, Tycho / Wu, Fan / Hoft, Carolin / Laplanche, Loic / Pang, Yan / Bolger, Michael B / Huehn, Eva / Lukacova, Viera / Mullin, James M / Szeto, Ke X / Costales, Chester / Lin, Jian / McAllister, Mark / Modi, Sweta / Rotter, Charles / Varma, Manthena / Wong, Mei / Mitra, Amitava / Bevernage, Jan / Biewenga, Jeike / Van Peer, Achiel / Lloyd, Richard / Shardlow, Carole / Langguth, Peter / Mishenzon, Irina / Nguyen, Mai Anh / Brown, Jonathan / Lennernäs, Hans / Abrahamsson, Bertil

    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

    2016  Volume 96, Page(s) 610–625

    Abstract: Orally administered drugs are subject to a number of barriers impacting bioavailability ( ... ...

    Abstract Orally administered drugs are subject to a number of barriers impacting bioavailability (F
    MeSH term(s) Administration, Oral ; Biopharmaceutics/methods ; Computer Simulation ; Drug Evaluation, Preclinical/methods ; Forecasting ; Humans ; Intestinal Absorption/drug effects ; Intestinal Absorption/physiology ; Models, Biological ; Pharmaceutical Preparations/administration & dosage ; Pharmaceutical Preparations/metabolism
    Chemical Substances Pharmaceutical Preparations
    Language English
    Publishing date 2016-11-02
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1154366-8
    ISSN 1879-0720 ; 0928-0987
    ISSN (online) 1879-0720
    ISSN 0928-0987
    DOI 10.1016/j.ejps.2016.10.036
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top